-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
-
Summary
-
Nurix Therapeutics, Inc. quarterly/annual Research and Development Expense history and change rate from Q3 2019 to Q3 2025.
- Nurix Therapeutics, Inc. Research and Development Expense for the quarter ending 31 Aug 2025 was $86,120,000.000, a 55.2% increase year-over-year.
- Nurix Therapeutics, Inc. Research and Development Expense for the twelve months ending 31 Aug 2025 was $301,103,000.000, a 47.5% increase year-over-year.
- Nurix Therapeutics, Inc. annual Research and Development Expense for 2024 was $221,632,000.000, a 17.2% increase from 2023.
- Nurix Therapeutics, Inc. annual Research and Development Expense for 2023 was $189,148,000.000, a 2.52% increase from 2022.
- Nurix Therapeutics, Inc. annual Research and Development Expense for 2022 was $184,497,000.000, a 58.5% increase from 2021.
Research and Development Expense, Trailing 12 Months (USD)
Research and Development Expense, Quarterly (USD)
Research and Development Expense, YoY Quarterly Change (%)
Research and Development Expense, Annual (USD)
Research and Development Expense, YoY Annual Change (%)